CSPC’s SYS6090 Shows 40% Objective Response in 10 Evaluable Liver Cancer Patients
CSPC reported a 40% objective response rate among 10 evaluable patients with liver cancer in a Phase I/II trial.
Related stories
Marconi Technologies Awarded U.S. Army Production Order for TRILOS
Marconi Technologies was awarded a production order to modernize TRILOS by the U.S. Army.
L impact | EQUITY | Oct 29, 2026, 04:35 PM UTC
Godrej Consumer Q2 Revenue Rises 19% Year on Year
Godrej Consumer Products reported higher revenue for the September quarter of fiscal 2027. Pricing actions and cost savings helped offset rising input costs.
M impact | EQUITY | Oct 29, 2026, 04:35 PM UTC
Higher Freight Rates Add $5.4 Billion to Shell's Debt
Shell said freight rates added $5.4 billion to shipping lease costs in the third quarter versus the previous three months, feeding into net debt. TotalEnergies said freight rates c
M impact | EQUITY | Oct 29, 2026, 04:35 PM UTC
Poundland Files Notice of Intention to Appoint Administrators
M impact | EQUITY | Oct 29, 2026, 04:34 PM UTC
Summi Group Delays Annual Results Publication Due to Audit Procedures
M impact | EQUITY | Oct 29, 2026, 04:34 PM UTC
Dynamix to Redeem Public Shares for About $10.71 Each
Dynamix will redeem all outstanding public shares for an estimated $10.71 per share after failing to complete a business combination by its deadline.
M impact | EQUITY | Oct 29, 2026, 04:33 PM UTC